(19)
(11) EP 4 580 673 A2

(12)

(88) Date of publication A3:
25.04.2024

(43) Date of publication:
09.07.2025 Bulletin 2025/28

(21) Application number: 23861547.0

(22) Date of filing: 30.08.2023
(51) International Patent Classification (IPC): 
A61K 39/39(2006.01)
C07K 16/32(2006.01)
C07K 16/28(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 2317/24; C07K 16/2863; C07K 2317/31; C07K 2317/34; C07K 2317/35; C07K 2317/55; C07K 2317/64; C07K 2317/732; C07K 2317/92; C07K 2317/622; A61K 2039/505
(86) International application number:
PCT/US2023/073194
(87) International publication number:
WO 2024/050439 (07.03.2024 Gazette 2024/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 31.08.2022 US 202263402945 P

(71) Applicant: SystImmune, Inc.
Redmond WA 98052 (US)

(72) Inventors:
  • HELGESON, Luke A.
    Sammamish, Washington 98075 (US)
  • ROZANITIS, Tyler C.
    Redmond, Washington 98052 (US)
  • GOULET, Dennis R.
    Redmond, Washington 98052 (US)
  • KHALILI, Jahan
    Kirkland, Washington 98034 (US)
  • DAVIS, Nicholas S.
    Seatle, Washington 98104 (US)
  • ZHU, Yi
    Chengdu, Sichuan (CN)

(74) Representative: Mathys & Squire 
The Shard 32 London Bridge Street
London SE1 9SG
London SE1 9SG (GB)

   


(54) BIEPITOPIC TETRAVALENT ANTIBODY TARGETING EGFR